SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy

BACKGROUND: Guidelines recommend to cease inflammatory bowel disease (IBD) biologic therapy during coronavirus disease 2019 (COVID-19). AIM: To investigate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody positivity in an IBD cohort, COVID-19 disease severity and to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Conti, Clara Benedetta, Mainardi, Elsa, Soro, Sara, Testa, Sophie, De Silvestri, Annalisa, Drago, Andrea, Cereatti, Fabrizio, Grassia, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984534/
https://www.ncbi.nlm.nih.gov/pubmed/35432745
http://dx.doi.org/10.4253/wjge.v14.i3.153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984534/
https://www.ncbi.nlm.nih.gov/pubmed/35432745
http://dx.doi.org/10.4253/wjge.v14.i3.153

Ejemplares similares